RESISTANCE IN UNCOMMON GENETIC DISORDERS: UNLOCKING THE POTENTIAL OF AI-DRIVEN PHARMACOGENOMICS

Multidrug resistance continues to be the principal barrier to the clinical treatment of uncommon genetic illnesses, severely impeding therapeutic outcomes. Traditional drug development models as well as treatment models do not take into account patient-specific genomic differences. The convergence of AI with pharmacogenomics demonstrates a strong base that can be leveraged to promote therapeutic precision and resistance. Reflecting the current individual-treatment-strategy focus necessary for patients with rare diseases, this review discusses the potential paradigm-shifting impact of AI-facilitated pharmacogenomic approaches in drug discovery. We describe how computational methods—such as machine learning and deep learning—can be used to predict pharmacologic performance, to discover new therapeutic targets, and to understand molecular mechanisms of multidrug resistance (MDR) in rare genetic diseases. Even with much advancement, significant barriers still exist in producing precision therapeutics that can effectively counter MDR, becoming rigorously clinically validated, and translating AI platforms to span diverse genomic datatypes. In stating these unmet gaps, we outline focused research directions that can address these gaps and enable the development of more effective, genomically informed therapeutic strategies bridging computational modeling and clinical translation. This review emphasizes how crucial interdisciplinary cooperation is to the development of AI-driven precision medicine for uncommon diseases, which has the potential to significantly enhance patient outcomes and therapeutic efficacy.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-18
DOI
https://doi.org/10.5281/zenodo.24334065
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

RESISTANCE IN UNCOMMON GENETIC DISORDERS: UNLOCKING THE POTENTIAL OF AI-DRIVEN PHARMACOGENOMICS

Navroop Kaur, Arshdeep Singh, Upasana, Saksham
3 links
Zenodo (CERN European Organization for Nuclear Research)
Computational Drug Discovery Methods
article

RESISTANCE IN UNCOMMON GENETIC DISORDERS: UNLOCKING THE POTENTIAL OF AI-DRIVEN PHARMACOGENOMICS

Navroop Kaur, Arshdeep Singh, Upasana, Saksham
article en

Abstract

Multidrug resistance continues to be the principal barrier to the clinical treatment of uncommon genetic illnesses, severely impeding therapeutic outcomes. Traditional drug development models as well as treatment models do not take into account patient-specific genomic differences. The convergence of AI with pharmacogenomics demonstrates a strong base that can be leveraged to promote therapeutic precision and resistance. Reflecting the current individual-treatment-strategy focus necessary for patients with rare diseases, this review discusses the potential paradigm-shifting impact of AI-facilitated pharmacogenomic approaches in drug discovery. We describe how computational methods—such as machine learning and deep learning—can be used to predict pharmacologic performance, to discover new therapeutic targets, and to understand molecular mechanisms of multidrug resistance (MDR) in rare genetic diseases. Even with much advancement, significant barriers still exist in producing precision therapeutics that can effectively counter MDR, becoming rigorously clinically validated, and translating AI platforms to span diverse genomic datatypes. In stating these unmet gaps, we outline focused research directions that can address these gaps and enable the development of more effective, genomically informed therapeutic strategies bridging computational modeling and clinical translation. This review emphasizes how crucial interdisciplinary cooperation is to the development of AI-driven precision medicine for uncommon diseases, which has the potential to significantly enhance patient outcomes and therapeutic efficacy.

Zenodo (CERN European Organization for Nuclear Research)
Guru Nanak Dev University (IN), Government Medical College, Amritsar (IN), Indian Institute of Management Amritsar (IN)
Good health and well-being
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon